GE Healthcare today said that Jean-Luc Vanderheyden has joined the company to lead its Molecular Imaging business.
In his new role, Vanderheyden will report to the general manager, to be named at a later date.
Prior to GE Healthcare, Vanderheyden was the vice-president of research and development for Theseus Imaging and director of nuclear medicine research and development for Mallinckrodt/Tyco Healthcare. He was also a visiting associate professor in nuclear medicine at the University of Massachusetts Medical School.
Jeremy Norris has joined Protein Discovery as director of mass spectrometry, the company said today.
Prior to joining Protein Discovery, Norris was an adjunct instructor of biochemistry at Vanderbilt University, where he received his Ph.D. in chemistry.
While at Vanderbilt, he was responsible for tissue imaging work for outside companies and for designing and implementing the university's Serum Proteomics Core.
Orchid Cellmark has appointed William J. Lutz to the newly created position of vice-president of information technology, the company said earlier this week.
Prior to his appointment, Lutz, was chief information officer at Genencor International, a biotechnology company recently acquired by Danisco. He was also director of information management and technology at Bausch and Lomb. He has held positions at NCR, General Electric, Fischer Scientific, and the State University of New York at Binghamton.
Columbia University awarded the 2005 Louisa Gross Horwitz Prize to Ada Yonath, the university said yesterday.
Yonath is the Martin S. and Helen Kimmel Professor of Structural Biology and director of the Helen and Milton A. Kimmelman Center for Biomolecular Structure at the Weizmann Institute of Science in Israel.
The Louisa Gross Horwitz Prize has been awarded annually since 1967 for research in the fields of biology and biochemistry.
Yonath has received the National Institutes of Health Certificate of Distinction, the F.A.
Cotton Medal for Excellence in Chemical Research, the 2000 Anfinsen Prize, the 2002 Harvey Prize for Natural Sciences, the 2002 Israel Prize for Chemical Research, the 2004 Massry Prize, and the 2004 Paul Karrer Gold Medal.
UK-based Cobra Biomanufacturing appointed Martin Comberbach, Paul Stockbridge and Tony Mulcahy to director positions, the company said today.
Comberbach, prior to his appointment as director of GMP manufacturing operations, held senior positions at GSK's Rixensart vaccine facility, Metris Therapeutics, and GeneMedix.
Stockbridge, the new director of quality, spent 23 years with Eli Lilly in the UK before moving to Aventis Pharma in 2002 as the head of quality operations. He is registered as a Qualified Person under the Permanent Provisions of the EU directives.
Mulcahy was the European director of business development and was promoted to director of customer relations. He's been with Cobra for 12 years.
American Healthways appointed Alison Taunton-Rigby to the Board of Directors, the company announced yesterday.
Founder and chief executive officer of Ribonovix, an early-stage biotechnology company developing antibiotics using a functional genomics technology, she currently serves on the boards of directors at Abt Associates, Idera Pharmaceuticals, RiverSource Funds (formerly American Express), Massachusetts Biotechnology Council, and The Children's Hospital in Boston.
Prior to Ribonovix, she was president, chief executive, and director of several private and publicly traded companies, including CMT, Aquila Biopharmaceuticals, Cambridge Biotech, and Mitotix. She has worked with Genzyme, Arthur D. Little, Vivotech, Biogen, and Collaborative Research.
Pathologist Scott W. Binder has joined CombiMatrix's wholly owned subsidiary, CombiMatrix Molecular Diagnostics, as a member of its Scientific Advisory Board, Acacia Research said earlier this week.
A professor of clinical pathology and dermatology, chief of dermatopathology, and director of pathology outreach services at the David Geffen School of Medicine at UCLA, he is the founder and director of a dermatopathology fellowship training program in California.
Binder received his B.A. and M.D. from the University of Chicago Medical School, completed his residency at the Department of Pathology and Laboratory Medicine at UCLA, and was a fellow with at the Scripps Clinic and Research Institute in La Jolla, CA. He completed a preceptorship at New York University.
Yvonne Linney has left Caliper Life Sciences and is now head of molecular marketing for Bayer Diagnostics.
At Caliper, she was director of marketing. Before that, she held several directorial and managerial positions with Amersham Biosciences, now GE Healthcare.
WellGen has enlisted industry veteran Arthur H. Finnel to be its first chief financial officer, the company said last week.
Most recently, Finnel was executive vice-president, treasurer and chief financial officer of Bionova Holding from 1995, prior to its acquisition by Savia S.A. de C.V. in 2004. Finnel held several executive positions at Mars Incorporated, such as vice-president of finance, treasurer, and general manager. He also held research, strategic planning and analyst positions at the Wharton Applied Research Center, Exxon, and the Busch Center of the University of Pennsylvania.